Targeted Lipid-Based Drug Delivery Systems for Lung Cancer Therapy

Abstract

The aim of this study was to review the literature to explore the lipid-based drug delivery systems that have been investigated for improved treatment of lung cancers. Such lipid-based drug delivery systems include microemulsions, liposomes, transferosomes, niosomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). In order to minimise the side effects of chemotherapeutic active pharmaceutical ingredients, surface modification with various ligands has been introduced so that the delivery system will attach only to specific receptors which are overexpressed in lung cancer cells. This review briefly explored cancers and their aetiologies and risk factors, especially lung cancer. It then discussed different modifications that have been performed on the drug delivery systems to successfully treat lung cancer. The use of different ligands has also been investigated in this review. The particle size of drug delivery systems after the attachment of the ligand remained small, varying from 75 to 189 nm, which was the most significant physicochemical property during development as it affected the delivery of particles to specific sites in the lungs. Overall, evidence suggests that surface modified lipid-based drug delivery systems have significant potential to revolutionise the treatment of lung cancer, leading to reduced side effects from chemotherapy.